Assessing Hepatitis E Virus Exposure in Blood Donors in Occitania, France
Determination of HEV Seroprevalence Among Blood Donors in Occitania
This study is testing how many blood donors in Occitania, France, have been exposed to the Hepatitis E virus to help improve safety in blood transfusions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06137313 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine the seroprevalence of Hepatitis E Virus (HEV) among blood donors in Occitania, France, in 2023. By comparing the current frequency of anti-HEV IgG and IgM markers with data from 2011, the study seeks to enhance understanding of HEV transmission dynamics. The methodology involves serological testing and the use of questionnaires to gather relevant epidemiological data. The findings could inform strategies to reduce the risk of HEV transmission through blood transfusions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who are blood donors residing in Occitania.
Not a fit: Patients who are not blood donors or those living outside the Occitania region may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved safety measures in blood transfusions, reducing the risk of HEV transmission to patients.
How similar studies have performed: Other studies have shown success in assessing seroprevalence of infectious diseases, indicating that this approach is both valid and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * blood donors Exclusion Criteria: \-
Where this trial is running
Toulouse
- Purpan University Hospital — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Jacques Izopet, MD — University Hospital, Toulouse
- Study coordinator: Jacques Izopet, MD
- Email: izopet.j@chu-toulouse.fr
- Phone: 567690422
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.